- Home
- NRDS vs EVMN Comparison
NRDS vs EVMN Comparison
Compare NRDS & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRDS | EVMN |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 892.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRDS | EVMN |
|---|---|---|
| Price | $10.49 | $26.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $14.33 | ★ $43.88 |
| AVG Volume (30 Days) | ★ 665.2K | 268.4K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.42 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $836,600,000.00 | N/A |
| Revenue This Year | $10.13 | N/A |
| Revenue Next Year | $7.11 | N/A |
| P/E Ratio | $16.88 | ★ N/A |
| Revenue Growth | ★ 21.67 | N/A |
| 52 Week Low | $8.21 | $13.89 |
| 52 Week High | $16.24 | $33.20 |
Technical Indicators
Market Signals| Indicator | NRDS | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 56.72 |
| Support Level | $10.14 | $21.14 |
| Resistance Level | $11.02 | $33.20 |
| Average True Range (ATR) | 0.37 | 1.98 |
| MACD | 0.06 | 0.40 |
| Stochastic Oscillator | 54.87 | 73.29 |
Price Performance
Historical ComparisonAbout NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.